Abiopharma

🔍 Welgus Howard G. (Director)

Company: Arcutis Biotherapeutics, Inc. (ARQT)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 110,206.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 10,000 shares of Common Stock at $15.6383 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 100,206.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 10,000 shares of Stock Option (right to buy) at $1.6806 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2029-03-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
• F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.45 to $15.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F3: This option is fully vested.